Sanofi - 06 Aug 2026 Form 4 Insider Report for Attovia Therapeutics, Inc. (ATTO)

Reporting relationship: 10%+ Owner
Issuer ticker: ATTO
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 15:45:54 UTC
Prior SEC filing: 04 Aug 2026
Next SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Alexandra Roger, as attorney-in-fact for Sanofi

Key filing fact

Sanofi filed Form 4 for Attovia Therapeutics, Inc. (ATTO) on 07 Aug 2026.

Key facts

This page summarizes Sanofi's Form 4 filing for Attovia Therapeutics, Inc. (ATTO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 15:45.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001121404 Primary reporting owner

Sanofi

Relationship: 10%+ Owner
Address: 46 AVENUE DE LA GRANDE ARMEE, PARIS, FRANCE
Signature: /s/ Alexandra Roger, as attorney-in-fact for Sanofi
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +782,855
Change %
Price
Shares after: 782,855
Date: 06 Aug 2026
Ownership: See footnote
Footnotes: F1, F3

ATTO transaction

Common Stock

Purchase

Transaction value
Shares: +300,000
Change %: +38%
Price: $17.00^*
Shares after: 1,082,855
Date: 06 Aug 2026
Ownership: See footnote
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATTO transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -782,855
Change %: -100%
Price
Shares after: 0
Date: 06 Aug 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 782,855
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Sanofi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.

Footnote F2

Represents a purchase in the Issuer's IPO.

Footnote F3

Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.

SEC remarks

Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock.